Clinical Trials
21 trialsNCT06680037 2026-05-18
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
Phase 1 Recruiting
NCT07526493 2026-05-12
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Tongji Hospital
Phase 1 Recruiting
NCT07085676 2026-05-06
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Hadassah Medical Organization
Phase 1 Recruiting
NCT00716066 2026-02-27
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
Fred Hutchinson Cancer Center
Phase 2 Active not recruiting
NCT07392528 2026-02-11
Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/ BCMA(QT-019C) in Patients With r/ r Neurological Autoimmune Diseases
Tianjin Huanhu Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT06939166 2025-12-15
Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases
Tianjin Huanhu Hospital
Phase EARLY_PHASE1 Recruiting
NCT04201262 2025-10-14
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT06249438 2025-07-25
CAR-AID
RenJi Hospital
Phase 1 Recruiting
NCT07022197 2025-06-15
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Tianjin Medical University General Hospital
Phase 1/2 Recruiting
NCT06485232 2025-01-01
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
Xuanwu Hospital, Beijing
Phase EARLY_PHASE1 Not yet recruiting
NCT04561557 2024-10-30
CARTinNS
Tongji Hospital
Phase EARLY_PHASE1 Recruiting
NCT04155424 2024-09-25
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc.
Phase 2/3 Terminated
NCT02003144 2022-08-23
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT00304291 2020-12-28
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
State University of New York at Buffalo
Phase 4 Completed
NCT01892345 2019-06-26
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
Alexion Pharmaceuticals, Inc.
Phase 3 Terminated
NCT02276963 2019-06-06
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Johns Hopkins University
Phase 1 Completed
NCT03138421 2019-01-25
Central Pain Study for ABX-1431
Abide Therapeutics
Phase 1 Completed
NCT02166346 2018-04-17
Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
Johns Hopkins University
Phase 2 Completed
NCT02398994 2016-07-20
STRIVE
Guy's and St Thomas' NHS Foundation Trust
Phase 3 Terminated
NCT00501748 2011-09-27
Safety and Tolerability of Rituximab in Neuromyelitis Optica
University of California, San Francisco
Phase 1 Completed
NCT00004645 2005-06-24
Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone
Office of Rare Diseases (ORD)
Phase 3 Unknown